Mechanisms of Skeletal Disease Mediated by Haematological

Total Page:16

File Type:pdf, Size:1020Kb

Mechanisms of Skeletal Disease Mediated by Haematological OF z a ) n Mechanisms of Skeletal Disease Mediated by Haematolo gical Malignancies Beiqing Pan B. Med. M. Med. Sc. Matthew Roberts Laboratory, Hanson Institute, Institute of Medical and Veterinary Science Department of Medicine, The University of Adelaide, South Australia A thesis submitted to the University of Adelaide in candidature for the degree of Doctor of Philosophy August 2004 TABLE OF CONTENTS DEGLARAT|ON......... """' l AGKNOWLEDGMENT.............. """' ll A8STRACT............. """'lv ABBREVIATIONS """""v1 PUBLICATIONS """"""'xl CHAPTER 1 GENERAL INTRODUCTION ......1 TO BONE 1.1 HAEMATOLOGICAL MALIGNANCIES WHICII GIBE RISE 1 LESIONS 2 1.1.1 Osteolytic Bone Disease Mediated by Multiple Myeloma 2 1.1.1.1 General Description...'.. 4 t.l.l.2 P athophysiolo gy of tvttvt 5 1.1.1.3 Osteolytic Bone Disease Lt.2 Osteoblastic Bone Disease Mediated by POEMS" 6 t.l.2.1 General DescriPtion...... 6 l.l.2.2 Pathophysiology of POEMS Syndrome. 1 8 1.1.2.3 Osteoblastic Bone Disease 1.2 BONE PHYSIOLOGY.............. 8 1.2.1 PhysiologicalBoneRemodelling 9 1.2.2 Bone ResorPtion 9 1.2.2.1 Osteoclasts 9 1.2.2.2 Osteoclast Stem Cells 1.2.3 BoneFormation.......'......... 1.2.3.1 Osteoblast Cells 1.2.3.2 OsteoblastStemCells..... 1.2.3.3 OsteocYtes '.".....' 1.2.3.4 Lining Cells FACTORS INVOLVED IN BONE LESIONS... t4 1.3 l6 1.3.1 Osteoclast Activating Factors (OAFÐ """"' 1.3.1.1 Interleukin-1P 16 1.3.1.2 Interleukin-6 t7 l8 1 .3.1 .3 Tumour Necrosis Factor-cx'...... 1.3.1.4 ParathyroidHormone Related Protein""""""' t9 1.3.2 RANKL/RANIIOPGSYStem 20 1.3.2.1 GeneralDescriPtion 20 1.3.2.2 RANKL/OPG Ratio and Bone Lesion 22 1.3.2.3 Incrçased RANKL/OPG Ratio in MM"' 22 1.3.2.4 The Regulation of RANKL/OPG Ratio in MM 23 1.3.3 Endothelin-1 (ET-l)'..'.'.... 26 1.3.3.1 ET-1Structure.... 26 26 1.3.3.2 Endothelin ConveÍing Enzyme-1 (ECE-1) .... 27 1 .3.3.3 ET- 1 Receptors ...............' t.3.3.4 The Expression and Function ofET-1 and Its Receptors"""' 30 l.3.3.5 ET-l and PathologY. 32 t.3.3.6 ET-l and Bone Cells 34 1.3.3.7 Application of ET-1 in Clinic 38 1.4 THE ROLE OF ANGIOGENESIS IN MM 38 t.4.1 Angiogenesis and Tumour Growth 39 1.4.2 Angiogenesis and Bone Remodelling 39 1.4.3 IL- 1 B and Angiogenesis.. :.........'...'..'... 40 1.4.4 RANKL and Angiogenesls'.......'....'.'.. 40 1.4.5 ET-l and Angiogenesis 1.5 1.6 1.7 GHAPTER 2 MATERIALS AND METHODS ............. ....44 .......44 2.1 CELL CULTURE. 44 2.r.1 Buffers and Media """"""""""" 2.1.1.l 2-Mercaptoethanol (2-ME) 44 2.1.1.2 Double-Strength Iscove's Modifred Dulbecco's Medium (2xrMDM)..44 2.r.1.3 10% (dv) Bovine Serum Albumin (BSA) 45 45 2.1.1.4 ThawMedium.. 45 2.1.1.5 Dulbecco' Modihed Eagles Medium-10 (DMEM-10) """"""""""""" 45 2.1.1.6 Roswell Park Memorial Institute Medium (RPMI-1640)-I0""""""""' 2.r.1;7 Alpha Modification of Minimum Essential Medium-10 (cr-MEM-l0).46 46 2.1.1.8 Serum Deprived Medium (SDM) ................ 46 2.7.2 Human Myeloma Cell Lines .............,., A7 2.1.3 Retroviral Packaging Cell Line PT67 "....'.'." 47 2.1.4 Murine Stromal Fibroblastic Cell Line, Swiss NIH-3T3 "' ..................,.,.. 47 2.1.5 Bone Marrow Mononuclear Cells (BMMNCs) """"""""' 48 2.1.6 BM CFU-F Clonogenic AssaY 48 2.1.7 Normal Human Bonc Cells (NHBC) 48 2.1.8 Normal Osteoblast Donor (NOD) 2.t.9 Co-culture of OBJike Cells with Myeloma Cells ' 49 2.1.10 2.t.tl 2.r.12 2.1.13 ', I CELL PROLIFERATION ASSAYS................... 50 50 2.2.1 Reagents Used in This StudY '.' 50 2.2.2 Cell Proliferation AssaY...' 2.3 EXAMINATION OF' GENE EXPRESSIONIN OSTEOBLAST-LIKE CELLS........ 2.3.1 TRIzolrM Isolation of Total RNA 2.3.2 Determination of RNA Concentration'...'.'...... " " " (PCR) 2.3.3 Reverse Transcription (RT) Polymerase Chain Reaction Amplifrcation of DNA 52 2.3.3.1 Synthesis of Complementary DNA (cDNA) ...'."' 53 2.3.3.1 P olymerase Chain Reaction (P CR) Amplifrcation of cDNA 2.3.4 Primers Used in This StudY.. 2.4IMMUNOLOGICALSTUDIESEXAMININGCELLSURF'ACE 54 54 2.4.1 Buffers and Fixatives 2.4.1.1 Blocking Buffer for Flow Cytometric Analysis" 2.4.1.2 Magnetic Activated Cell Sorting Buffer (MACS Buffers).. 54 2.4.r.3 Flow Cytometry Fixative (FACS Fix) ' 54 2.4.2 Single-Colour Flow Cytometric Analysis 55 2.4.3 Two-Colour Flow Cytometric Analysis 55 2.4.4 Three-Colour Flow Cytometric Analysis 56 2.4.5 Detection of Intracellular Antigens......'.. of OB- 2.4.6 Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Labelling like Cells 57 57 2.4.7 Fluorescence-Activated Cell Sorling (FACS)...."" 2.4.8 Magnetic Activated Cell Sorting (MACS)'..'." 2.4.9 Immunofluorescence Staining for Confocal Microscopy' " " " " 2.4.10 Antibodies Used in This Study......'... 2,s PREPARATION oF A RETROVIRAL CONSTRUCT HARBOURING THE HUMAN ET-l cDNA 2.5.1 Buffers and Reagents 2.5.1.1 Luria-Bertani (LB) Broth' 2.5 .l .2 L-agat Plates ... '.. '... ' 2.5.1.3 SOC Medium'... 2.5.2 DNA SYnthesis bY PCR using Pfu DNA PolYmerase 2.5.3 Restriction Digestion of pRUFneo Vector and PCR Product 2.5.4 Extraction of DNA from Agarose Gels 2.5.5 Ligation of Insert to Vector 2.5.6 Prèparation of Electrocompetent DHI0B Cells for Transformations ...... 2.5.7 Transformation of Competent Cells. "... 2.5.8 Isolation and Analysis of Plasmid DNA"""""" 2.5.9 Automated DNA Sequence Analysis.' 2.5.10 Transfection of the Retroviral Packaging cell Line PT67 Using 63 2.5.ll Retroviral Infcction of OB-Like Cells and Myeloma Cells """"""""""' 64 2.6 IN VITRO ASSAY OF BONE FORMING POTENTIAL """'64 2.7 IN VIVO ASSAYS OF BONE FORMTNG POTENTrAL"""""""""""""" 65 66 2.8 ELISA MEASUREMENT OF SOLUBLE PROTEIN 66 2.8.1 ET-l Level in BM and PB Plasma and Cell Supematant 2.8.2 Determination of IL-lB, IL-6, OPG and TNF-cr Levels in Culture Supernatants... 6',7 2.9 WESTERN BLOT A¡IALYSIS 68 2.9.1 Buffers and Reagents 68 2.9.1.1 Tris-Saline-EDTA(TSE). 68 2.9.r.2 t% (vlv) NP4O-TSE. 68 2.9.r.3 0.1% (v/v) NP4O-TSE..' 68 2.9.1.4 25x Protease Inhibitor Cocktail "' 69 69 2.9.1.5 1x Reducing SamPle Buffer 69 2.9.1.6 1 x Non-reducing Sample Buffer.'.'.........'..'. 2.9.t.1 Electrophoresis "Rururing" buffer....'........... 69 69 2.9.1.8 Transfer Buffer... 69 2.9.1.9 Separating Buffer 69 2.9.1.10 Stacking Buffer............'...... 69 2.9.1.11 PBST.. 69 2.9.2 Preparation of Cell Lysates....'.... 70 2.9.3 Immunoprecipitaiton (IP) with Dlmabeads 70 2.9.4 Western Blot AnalYsis .'.. CHAPTER 3. THE MULTIPLE MYELOMA.DERIVED PRO- TNFLAMMATORY GYTOKINE, lL'1p, INHIBITS BONE FORMATION AND ENHANCES OSTEOCLATOGENESIS BY INCREASING THE NUMBER OF RANKL-EXPRESSING STRO'1 POSITIVE OSTEOPROGENITOR CELLS 72 3.1 INTRODUCTION """'72 3.2 3.2.r 3.2.2 3.2.3 3.2.4 3.2.5 3.2.6 Exposure... 19 of OB-Like 3.2.',7 IL-lB Does not Impair the Bone Mineral Forming Capacity Cells under Osteoinductive Condition 80 * I Cells Possess an Enhanced CapacitY 3.2.8 IL- 1 B -upregulated STRO- OB-like to Support Osteoclastogenesis' 80 CHAPTER 4. THE POTENT OSTEOGLASTOGENIC FACTOR' RANKL, IS A MARKER OF IMMATURE OSTEOPROGENITOR GELLSANDBoNEMARRoWSTRoMALSTEMGELLS...........92 4.1 INTRODUCTION """'92 94 4.2 RESULTS.. 94 4.2.1 Human OB-like Cells Co-express STRO-1 and TM-RANKL"""""""""' 4.2.2 HumanBMMNCsCo-expressSTRo-landTM-RANKLontheCell Surface. 94 4.2.3 Distribution of STRO-I and RANKL on BMMNCs 95 to a Population 4.2.4 colony Forming units-Fibroblastic (cFU-F) are Restricted orsMMNCs Wtti"n Express RANKL and STRO-I at High Levels......... 95 96 4.2.5 RANKL and STRO-I aie Highly Associated Molecules """"""""""""" 98 GHAPTER 5. ELEVATED SERUM LEVELS OF THE VASOPEPTIDE, ET.1, MAY ACCOUNT FOR THE SUPPRESSI ON OF BONE FORMATION IN MYELOMA PATIENTS........... 102 5.2 5.2.1 \)') 5.2.3 5.2.4 5.2.5 5.2.6 5.2.7 5.3 DrscussroN................. """"""""' 111 CHAPTER 6. GENERAL DISGUSSION AND FUTURE CONSTDERATTONS .....120 BIBLIoGRAPHY...... ""126 Errata Errata o Table of contents, 1.1 and Page 2, section 1.1 : "GIBE" should be "GIVE" o Page VI, BMPs: "marphogenetic" shOUld be "mOrphogenetic" o Page 3, line 10: ">3/dl" should be ">3gldl" o Page 4, 12 lines up: "lyphocyte" should be "lymphocyte" "a o page 9, line 5-6: "a calcified connective tissue matrix (hydroxyapatite)" should be calcified (highly-substituted hydroxyapatite) connective tissue matrix" physiology" o page 9, 14 lines up: "In the normal physiology" should be "In normal o page 11, l't paragraph: "Osteoblasts are derived from the stromal or mesenchymal cell the stromal or system and represent..." should be "Osteoblast lineage is derived from mesenchymal cell system and represented by' "" o Page 15, 15 lines up: "ostolytic" should be "osteolytic" o Page 76, 14 lines up: "cycloocygenase" should be "cyclooxygenase" o Page 18, 7 lines up: "macrophage" should be "macrophages" o Page 20,line 13: "an" should be "and" o Page 35, line 2: "localises to in" should be "localises in" lines up o page 40, 13lines up: "Collin, 2001 #51 1" should be "Collin-Osdoby et a1.,2001";3 "Le Brun, l99g # 765" should be "Le Brun et al',1999" o Page 43,line 2: "...one of major..." should be "...one of the major.
Recommended publications
  • Cellular Responses to Erbb-2 Overexpression in Human Mammary Luminal Epithelial Cells: Comparison of Mrna and Protein Expression
    British Journal of Cancer (2004) 90, 173 – 181 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression SL White1, S Gharbi1, MF Bertani1, H-L Chan1, MD Waterfield1 and JF Timms*,1 1 Ludwig Institute for Cancer Research, Wing 1.1, Cruciform Building, Gower Street, London WCIE 6BT, UK Microarray analysis offers a powerful tool for studying the mechanisms of cellular transformation, although the correlation between mRNA and protein expression is largely unknown. In this study, a microarray analysis was performed to compare transcription in response to overexpression of the ErbB-2 receptor tyrosine kinase in a model mammary luminal epithelial cell system, and in response to the ErbB-specific growth factor heregulin b1. We sought to validate mRNA changes by monitoring changes at the protein level using a parallel proteomics strategy, and report a surprisingly high correlation between transcription and translation for the subset of genes studied. We further characterised the identified targets and relate differential expression to changes in the biological properties of ErbB-2-overexpressing cells. We found differential regulation of several key cell cycle modulators, including cyclin D2, and downregulation of a large number of interferon-inducible genes, consistent with increased proliferation of the ErbB-2- overexpressing cells. Furthermore, differential expression of genes involved in extracellular matrix modelling and cellular adhesion was linked to altered adhesion of these cells. Finally, we provide evidence for enhanced autocrine activation of MAPK signalling and the AP-1 transcription complex.
    [Show full text]
  • Endothelin-2 Signaling in the Neural Retina Promotes the Endothelial Tip Cell State and Inhibits Angiogenesis
    Endothelin-2 signaling in the neural retina promotes PNAS PLUS the endothelial tip cell state and inhibits angiogenesis Amir Rattnera,1, Huimin Yua, John Williamsa,b, Philip M. Smallwooda,b, and Jeremy Nathansa,b,c,d,1 Departments of aMolecular Biology and Genetics, cNeuroscience, and dOphthalmology and bHoward Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205 Contributed by Jeremy Nathans, August 20, 2013 (sent for review February 19, 2013) Endothelin signaling is required for neural crest migration and time lapse imaging studies of vascular development in zebrafish homeostatic regulation of blood pressure. Here, we report that and mammalian EC dynamics in explant culture show that the tip constitutive overexpression of Endothelin-2 (Edn2) in the mouse cell and stalk cell states are highly plastic, with frequent retina perturbs vascular development by inhibiting endothelial cell exchanges between the two cell states (8, 9). migration across the retinal surface and subsequent endothelial Several other signaling pathways are also essential for retinal cell invasion into the retina. Developing endothelial cells exist in vascular development. Norrin, a Muller-glia–derived ligand, and one of two states: tip cells at the growing front and stalk cells in its EC receptor Frizzled4 (Fz4), coreceptor Lrp5, and receptor the vascular plexus behind the front. This division of endothelial chaperone Tspan12 activate canonical Wnt signaling in de- cell states is one of the central organizing principles of angiogen- veloping ECs (10). In humans and mice, defects in any of these esis. In the developing retina, Edn2 overexpression leads to components lead to retinal hypovascularization.
    [Show full text]
  • ADIPOR1 Is Essential for Vision and Its RPE Expression Is Lost in the Mfrp Valentin M Sluch
    The Jackson Laboratory The Mouseion at the JAXlibrary Faculty Research 2018 Faculty Research 9-25-2018 ADIPOR1 is essential for vision and its RPE expression is lost in the Mfrp Valentin M Sluch Angela Banks Hui Li Maura A Crowley Vanessa Davis See next page for additional authors Follow this and additional works at: https://mouseion.jax.org/stfb2018 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons Recommended Citation Sluch, Valentin M; Banks, Angela; Li, Hui; Crowley, Maura A; Davis, Vanessa; Xiang, Chuanxi; Yang, Junzheng; Demirs, John T; Vrouvlianis, Joanna; Leehy, Barrett; Hanks, Shawn; Hyman, Alexandra M; Aranda, Jorge; Chang, Bo; Bigelow, Chad E; and Rice, Dennis S, "ADIPOR1 is essential for vision and its RPE expression is lost in the Mfrp" (2018). Faculty Research 2018. 197. https://mouseion.jax.org/stfb2018/197 This Article is brought to you for free and open access by the Faculty Research at The ousM eion at the JAXlibrary. It has been accepted for inclusion in Faculty Research 2018 by an authorized administrator of The ousM eion at the JAXlibrary. For more information, please contact [email protected]. Authors Valentin M Sluch, Angela Banks, Hui Li, Maura A Crowley, Vanessa Davis, Chuanxi Xiang, Junzheng Yang, John T Demirs, Joanna Vrouvlianis, Barrett Leehy, Shawn Hanks, Alexandra M Hyman, Jorge Aranda, Bo Chang, Chad E Bigelow, and Dennis S Rice This article is available at The ousM eion at the JAXlibrary: https://mouseion.jax.org/stfb2018/197 www.nature.com/scientificreports OPEN ADIPOR1 is essential for vision and its RPE expression is lost in the Mfrprd6 mouse Received: 20 April 2018 Valentin M.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • Endothelin-2 Deficiency Causes Growth Retardation, Hypothermia, and Emphysema in Mice
    Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice Inik Chang, … , Roderick R. McInnes, Masashi Yanagisawa J Clin Invest. 2013;123(6):2643-2653. https://doi.org/10.1172/JCI66735. Research Article Endocrinology To explore the physiological functions of endothelin-2 (ET-2), we generated gene-targeted mouse models. GlobalE t2 knockout mice exhibited severe growth retardation and juvenile lethality. Despite normal milk intake, they suffered from internal starvation characterized by hypoglycemia, ketonemia, and increased levels of starvation-induced genes. Although ET-2 is abundantly expressed in the gastrointestinal tract, the intestine was morphologically and functionally normal. Moreover, intestinal epithelium–specific Et2 knockout mice showed no abnormalities in growth and survival. Global Et2 knockout mice were also profoundly hypothermic. Housing Et2 knockout mice in a warm environment significantly extended their median lifespan. However, neuron-specific Et2 knockout mice displayed a normal core body temperature. Low levels of Et2 mRNA were also detected in the lung, with transient increases soon after birth. The lungs ofE t2 knockout mice showed emphysematous structural changes with an increase in total lung capacity, resulting in chronic hypoxemia, hypercapnia, and increased erythropoietin synthesis. Finally, systemically inducible ET-2 deficiency in neonatal and adult mice fully reproduced the phenotype previously observed in global Et2 knockout mice. Together, these findings reveal that ET-2 is critical for the growth and survival of postnatal mice and plays important roles in energy homeostasis, thermoregulation, and the maintenance of lung morphology and function. Find the latest version: https://jci.me/66735/pdf Research article Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice Inik Chang,1 Alexa N.
    [Show full text]
  • Endothelins (EDN1, EDN2, EDN3) and Their Receptors (EDNRA, EDNRB, EDNRB2) in Chickens Functional Analysis and Tissue Distributi
    General and Comparative Endocrinology 283 (2019) 113231 Contents lists available at ScienceDirect General and Comparative Endocrinology journal homepage: www.elsevier.com/locate/ygcen Endothelins (EDN1, EDN2, EDN3) and their receptors (EDNRA, EDNRB, EDNRB2) in chickens: Functional analysis and tissue distribution T ⁎ Haikun Liu, Qin Luo, Jiannan Zhang, Chunheng Mo, Yajun Wang, Juan Li Key Laboratory of Bio-resources and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, PR China ARTICLE INFO ABSTRACT Keywords: Endothelins (EDNs) and their receptors (EDNRs) are reported to be involved in the regulation of many phy- Chicken siological/pathological processes, such as cardiovascular development and functions, pulmonary hypertension, Endothelin neural crest cell proliferation, differentiation and migration, pigmentation, and plumage in chickens. However, Endothelin receptor the functionality, signaling, and tissue expression of avian EDN-EDNRs have not been fully characterized, thus Tissue expression impeding our comprehensive understanding of their roles in this model vertebrate species. Here, we reported the cDNAs of three EDN genes (EDN1, EDN2, EDN3) and examined the functionality and expression of the three EDNs and their receptors (EDNRA, EDNRB and EDNRB2) in chickens. The results showed that: 1) chicken (c-) EDN1, EDN2, and EDN3 cDNAs were predicted to encode bioactive EDN peptides of 21 amino acids, which show remarkable degree of amino acid sequence identities (91–95%) to their respective mammalian orthologs; 2) chicken (c-) EDNRA expressed in HEK293 cells could be preferentially activated by chicken EDN1 and EDN2, monitored by the three cell-based luciferase reporter assays, indicating that cEDNRA is a functional receptor common for both cEDN1 and cEDN2.
    [Show full text]
  • Correlation Between Saliva and Plasma Levels of Endothelin Isoforms ET-1, ET-2, and ET-3
    Hindawi Publishing Corporation International Journal of Peptides Volume 2015, Article ID 828759, 7 pages http://dx.doi.org/10.1155/2015/828759 Research Article Correlation between Saliva and Plasma Levels of Endothelin Isoforms ET-1, ET-2, and ET-3 Roma Gurusankar,1 Prem Kumarathasan,2 Anusha Saravanamuthu,2 Errol M. Thomson,1 and Renaud Vincent1 1 Inhalation Toxicology Laboratory, Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON, Canada K1A 0K9 2Analytical Biochemistry and Proteomics Laboratory, Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON, Canada K1A 0K9 Correspondence should be addressed to Renaud Vincent; [email protected] Received 17 January 2015; Revised 17 March 2015; Accepted 18 March 2015 Academic Editor: Kazuhiro Takahashi Copyright © 2015 Roma Gurusankar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Although saliva endothelins are emerging as valuable noninvasive cardiovascular biomarkers, reports on the relationship between isoforms in saliva and plasma remain scarce. We measured endothelins in concurrent saliva and plasma samples (=30males; age 18–63) by HPLC-fluorescence. Results revealed statistically significant positive correlations among all isoforms between saliva and plasma: big endothelin-1 (BET-1, 0.55 ± 0.27 versus 3.35 ± 1.28 pmol/mL; = 0.38, = 0.041), endothelin-1 (ET-1, 0.52 ± 0.21 versus 3.45 ± 1.28 pmol/mL; = 0.53, = 0.003), endothelin-2 (ET-2, 0.21 ± 0.07 versus 1.63 ± 0.66 pmol/mL; = 0.51, = 0.004), and endothelin-3 (ET-3, 0.39 ± 0.19 versus 2.32 ± 1.44 pmol/mL; = 0.75, < 0.001).
    [Show full text]
  • Elevated Plasma Endothelin in Patients with Diabetes Mellitus
    Diabetologia (1990) 33:306-310 Diabetologia Springer-Verlag 1990 Elevated plasma endothelin in patients with diabetes mellitus K. Takahashi, M. A. Ghatei, H.-C. Lam, D. J. O'Halloran and S. R. Bloom Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK Summary. Plasma concentrations of endothelin, a vasocon- noreactive-endothelin showed three forms, one in a very big strictor peptide released from vascular endothelial cells, have molecular weight position, one intermediate and one in the been measured by radioimmunoassay in 100 patients with position of endothelin-1 itself. No material appeared in the diabetes mellitus and 19 healthy subjects. The plasma immu- positions of endothelin-2 and 3. Chromatographic analysis of noreactive-endothelin concentrations were found to be normal plasma showed only the big molecular weight peak greatly raised in the patients with diabetes (I ,880 + 120 fmol/1, while material in the endothelin-1, 2 or 3 positions was below mean + SEM) compared with the healthy subjects (540 + 50 detection. The elevation of endothelin in diabetic patients fmol/1, p < 0.005). The elevation of immunoreactive-endo- may be a marker of, and further exacerbate, their vascular dis- thelin could not be explained by secondary changes in blood ease. pressure or renal disease and did not correlate with the presence of diabetic retinopathy, duration of diabetes melli- Key words: Endothelin, radioimmunoassay, diabetes melli- tus, fasting blood glucose or serum fructosamine. Fast protein tus, fast protein liquid chromatography, endothelial cell, an- liquid chromatographic analysis of the diabetic plasma immu- giopathy. Angiopathy is a major complication in diabetes mellitus [1, Subjects and methods 2].
    [Show full text]
  • The Endothelin Axis in DNA Damage and Repair: the Cancer Paradigm
    Chapter 13 The Endothelin Axis in DNA Damage and Repair: The Cancer Paradigm Panagiotis J. Vlachostergios and Christos N. Papandreou Additional information is available at the end of the chapter http://dx.doi.org/10.5772/53977 1. Introduction Maintenance of genomic stability is central to cellular homeostasis and self defense from en‐ vironmental or intracellular inducers of DNA damage. Depending on the type of DNA le‐ sion, several DNA repair mechanisms exist. Each major DNA repair process involves the detection of DNA damage, the accumulation of DNA repair factors at the site of damage and finally the physical repair of the lesion [1, 2]. The simplest, single enzyme DNA repair pathway is direct reversal or repair (DR) which is effected by O6-methylguanine-methyltransferase (MGMT), which is an enzyme that directly reverses DNA alkylation damage at the O6 position of guanine residues [2]. The mismatch repair (MMR) pathway is responsible for repair of ‘insertion and deletion’ loops that form during DNA replication [3]. These errors cause base ‘mismatches’ in the DNA sequence that distort the helical structure of DNA. Key MMR proteins MSH2 and MLH1 are involved in detection of this distortion and excision of the mismatch site which is then followed by new DNA synthesis. DR is closely associated with MMR as a reduction in MGMT expression resulting from gene promoter methylation in some tumors, such as gliomas, results in recognition of resultant DNA mismatches by MMR and ultimate stimulation of pro-apoptotic signals after treatment with the alkylating agent temozolomide [4]. Repair of DNA alkylation products, oxidative lesions and single strand breaks (SSBs) is orchestrated by the base excision repair (BER) pathway.
    [Show full text]
  • And Postmenopausal Women
    153 In vitro effects of endothelin-1 on the contractility of myometrium obtained from pre- and postmenopausal women E Domali1,2, E Asprodini3, P A Molyvdas2 and I E Messinis1 1Department of Obstetrics and Gynecology, University of Thessalia, 22 Papakiriazi Street, 41222 Larissa, Greece 2Department of Physiology, University of Thessalia, 22 Papakiriazi Street, 41222 Larissa, Greece 3Department of Pharmacology, University of Thessalia, 22 Papakiriazi Street, 41222 Larissa, Greece (Requests for offprints should be addressed to I E Messinis) Abstract This study was conducted to evaluate the responsiveness of (2·80·5 g, n=6), the AUC (24·73·3 gmin, n=6), human nonpregnant myometrium to endothelin 1 (ET1) as well as the basal tone (183·621%, n=6) compared (1010 M-106 M) and KCl (80 mM) in relation to the with the two premenopausal groups. In all three groups hormonal profile of the women, who were allocated into KCl exposure induced an initial rise (mean amplitude three groups: group 1, premenopausal follicular phase, value: 1·1 g) followed by a relaxation phase to the primal n=14, group 2, premenopausal luteal phase, n=20, and baseline level (mean duration value: 12 min). Addition of group 3, postmenopausal women, n=12. At a concen- ET1 (106 M) to KCl (80 mM) induced a similar pattern tration of 106 M, ET1 in both groups 1 and 2 induced of contractility to that evoked by ET1 alone which, very low ripples of high frequency (group 1: 8014%, compared with KCl alone lasted significantly longer n=5, group 2: 31463%, n=11; P<0·05 compared with (P<0·05) in all three groups (group 1: 202 min, n=6; the pretreatment frequency) which lasted significantly group 2: 232 min, n=6; group 3: 353 min, n=5).
    [Show full text]
  • Activation of the Endothelin System Mediates Pathological Angiogenesis During Ischemic Retinopathy
    The American Journal of Pathology, Vol. 184, No. 11, November 2014 ajp.amjpathol.org GROWTH FACTORS, CYTOKINES, AND CELL CYCLE MOLECULES Activation of the Endothelin System Mediates Pathological Angiogenesis during Ischemic Retinopathy Chintan Patel,*yz S. Priya Narayanan,*yz Wenbo Zhang,*x Zhimin Xu,*y Sangeetha Sukumari-Ramesh,k Krishnan M. Dhandapani,k R. William Caldwell,y** and Ruth B. Caldwell*y{yy From the Vascular Biology Center,* the Vision Discovery Institute,y the College of Allied Health Sciences,z and the Departments of Neurosurgery,k Pharmacology and Toxicology,** and Cellular Biology and Anatomy,yy Georgia Regents University, Augusta, Georgia; the Departments of Ophthalmology and Visual Sciences,x University of Texas Medical Branch, Galveston, Texas; and the the Charlie Norwood VA Medical Center,{ Augusta, Georgia Accepted for publication July 15, 2014. Retinopathy of prematurity adversely affects premature infants because of oxygen-induced damage of the immature retinal vasculature, resulting in pathological neovascularization (NV). Our pilot studies Address correspondence to Ruth B. Caldwell, Ph.D., using the mouse model of oxygen-induced retinopathy (OIR) showed marked increases in angiogenic Vascular Biology Center, mediators, including endothelins and endothelin receptor (EDNR) A. We hypothesized that activation of Georgia Regents University, the endothelin system via EDNRA plays a causal role in pathological angiogenesis and up-regulation of 1459 Laney Walker Blvd, angiogenic mediators, including vascular endothelial growth factor A (VEGFA) in OIR. Mice were Room CB-3209A, Augusta, GA exposed to 75% oxygen from post-natal day P7 to P12, treated with either vehicle or EDNRA antagonist 30912. E-mail: rcaldwel@gru. BQ-123 or EDNRB antagonist BQ-788 on P12, and kept at room air from P12 to P17 (ischemic phase).
    [Show full text]
  • Original Article
    Artigo Original Big Endotelina-1 e Óxido Nítrico em Pacientes Idosos Hipertensos com e sem Síndrome da Apneia-Hipopneia Obstrutiva do Sono Big Endothelin-1 and Nitric Oxide in Hypertensive Elderly Patients with and without Obstructive Sleep Apnea-Hypopnea Syndrome Iara Felicio Anunciato, Rômulo Rebouças Lobo, Eduardo Barbosa Coelho, Waldiceu Aparecido Verri Jr., Alan Luiz Eckeli, Paulo Roberto Barbosa Évora, Fernando Nobre, Júlio César Moriguti, Eduardo Ferriolli, Nereida Kilza da Costa Lima Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, SP – Brasil Resumo Fundamento: O papel do estresse oxidativo em pacientes idosos hipertensos com síndrome de apneia-hipopneia obstrutiva do sono (SAHOS) é desconhecido. Objetivo: O objetivo foi avaliar os níveis de Big Endotelina-1 (Big ET-1) e Óxido Nítrico (NO) em pacientes idosos hipertensos com e sem SAHOS moderada a grave. Métodos: Os voluntários permaneceram internados durante 24 horas. Obtivemos os seguintes dados: índice de massa corporal (IMC), Monitorização Ambulatorial da Pressão Arterial (MAPA) – 24 horas, e medicação atual. Sangue arterial foi coletado às 7:00 h e às 19:00 h para determinar níveis plasmáticos de NO e Big ET-1. A oximetria de pulso foi realizada durante o sono. A correlação de Pearson, Spearman e análise de variância univariada foram utilizadas para a análise estatística. Resultados: Foram estudados 25 sujeitos com SAHOS (grupo 1) e 12 sem SAHOS (grupo 2), com idades de 67,0 ± 6,5 anos, 67,8 ± 6,8 anos, respectivamente. Não foram observadas diferenças significativas entre os grupos em IMC; no número de horas de sono; PA diastólica e sistólica em 24 h; PA de vigília; PA no sono; ou medicamentos usados para controlar a PA.
    [Show full text]